December 18, 2020 -- Enesi Pharma is collaborating with Robin Shattock, PhD, a leading infectious disease and vaccine expert, and his group at Imperial College London to develop RNA vaccines -- including those against SARS-CoV-2 -- that are stable at ambient temperatures and up to 40˚ C (104˚ F).
Such vaccines could minimize or eliminate the cold-chain requirements for global deployment and mass vaccination programs, the two said in a press release. The collaboration will combine Enesi's ImplaVax technology for the creation of thermostable, solid dose vaccines with RNA vaccines based on Imperial's self-amplifying RNA (saRNA) technology. The collaboration will also use Polyplex DNA/RNA stabilization technologies.
ImplaVax technology allows for the creation of solid-dose vaccines of a fixed dose that are designed to be delivered into the dermal layer of the skin using a needle-free device and with minimal administrator training.
Based on the results of a successful early collaboration, Enesi and Imperial are entering a new phase to develop and evaluate the effectiveness of RNA vaccines using saRNA, Polyplex, and ImplaVax technologies.
If the collaboration is successful, it could lead to a further partnership to develop an ImplaVax version of Imperial's RNA vaccine against SARS-CoV-2, which is based on the virus' spike protein and is being investigated in a phase I/II trial in over 400 healthy subjects.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
